Data / Drug companies / Dasatinib
Dasatinib: 18 companies and 108 products in the FDA NDC directory
Dasatinib is listed in the FDA National Drug Code Directory by 18 companies, with 108 products in commercial distribution. 90 of the products (83.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, and the newest product started marketing on November 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 18
- Products
- 108
- Generic (ANDA) products
- 90 (83.3%)
- Application numbers
- 12
- Routes
- Oral
- Brand names
- Sprycel, Phyrago
- openFDA record search
- api.fda.gov
Companies that list dasatinib
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alembic Pharmaceuticals Inc. | 6 | tablet, film coated | Generic drugs (ANDA) | November 11, 2025 |
| Alembic Pharmaceuticals Limited | 6 | tablet, film coated | Generic drugs (ANDA) | November 11, 2025 |
| Apotex Corp. | 6 | tablet, film coated | Generic drugs (ANDA) | September 3, 2024 |
| Aurobindo Pharma Limited | 6 | tablet | Generic drugs (ANDA) | April 22, 2025 |
| AvKARE | 6 | tablet, film coated | Generic drugs (ANDA) | November 18, 2025 |
| Biocon Pharma Inc. | 6 | tablet, film coated | Generic drugs (ANDA) | March 3, 2025 |
| BluePoint Laboratories | 6 | tablet, film coated | Generic drugs (ANDA) | December 5, 2025 |
| Cycle Pharmaceuticals Ltd | 6 | tablet | New drug applications (NDA) | September 22, 2025 |
| Dr. Reddy's Laboratories Inc. | 6 | tablet, film coated | Generic drugs (ANDA) | March 3, 2025 |
| E.r. Squibb & Sons, L.L.C. | 6 | tablet | New drug applications (NDA) | October 28, 2010 |
| Lupin Pharmaceuticals, Inc. | 6 | tablet | Generic drugs (ANDA) | January 30, 2026 |
| NorthStar RxLLC | 6 | tablet, film coated | Generic drugs (ANDA) | June 1, 2026 |
| Novadoz Pharmaceuticals LLC | 6 | tablet | Generic drugs (ANDA) | September 11, 2026 |
| Prasco Laboratories | 6 | tablet | Authorized generics (NDA) | September 3, 2024 |
| Quallent Pharmaceuticals Health LLC | 6 | tablet, film coated | Generic drugs (ANDA) | November 2, 2026 |
| Teva Pharmaceuticals, Inc. | 6 | tablet, film coated | Generic drugs (ANDA) | September 18, 2025 |
| Zydus Lifesciences Limited | 6 | tablet | Generic drugs (ANDA) | March 3, 2025 |
| Zydus Pharmaceuticals USA Inc. | 6 | tablet | Generic drugs (ANDA) | March 3, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 60 | 55.6% |
| Tablet | 48 | 44.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 90 | 83.3% |
| New drug applications (NDA) | 12 | 11.1% |
| Authorized generics (NDA) | 6 | 5.6% |
Pharmacologic classes
| Class | Products |
|---|---|
| Kinase Inhibitor | 108 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.